

What will the EXPAND Study involve?

The EXPAND Study will look at how well the body tolerates the investigational medication and whether it works in people with CAE and JAE.

The investigational medication will be compared with a placebo. A placebo looks like the investigational medication but contains no active substance. Participants who join the study will receive the investigational medication or placebo. If they receive placebo, they will take it during the first 2 weeks of the study and they will then receive the investigational medication.

The study medication (investigational medication or placebo) needs to be taken by mouth twice each day, once in the morning and once in the evening.



Participation in the study will last for up to 23 weeks (about 5 months) and will involve up to 13 study visits and 1 telephone call. Some of the study visits may be done from your home, if applicable in your country.

Participants who complete the study may be asked to join a long-term extension study to receive the investigational medication for a longer period.

Who can take part?

You or someone you care for may be able to take part if you/they:

- are 2 to 25 years of age
- have been diagnosed with CAE or JAE
- have not had tonic-clonic seizures in the past

What else do I need to consider?

- The study team will explain the possible benefits and risks of the study.
- If you (and/or your child, as applicable) choose to take part in the study, you can stop participating at any time.
- You will not be paid for your (or your child's) contribution to this study, but you may be reimbursed for reasonable travel costs during participation.
- The study medication and study-related tests will be provided at no cost to you.
- A team of doctors and nurses will carefully monitor your (or your child's) health during the study.

How do I get more information?




To find out more about the EXPAND Study, please visit www.expandstudy.com, or contact the study team using the information provided. Study participation is voluntary. By contacting us, you are under no obligation to take part in the study.

Deciding to take part in a clinical research study is your decision. If you have any questions, you can contact the study team using the information provided in this brochure.



WE'RE LOOKING TO CHANGE THE RESEARCH LANDSCAPE FOR PEOPLE LIVING WITH ABSENCE SEIZURES



The Expand Study will research an investigational medication for children and young adults with absence epilepsy.

Participant Information



What is a clinical research study?



A clinical research study is a medical study that helps to answer important questions about an investigational medication, such as:

- Does it work?
- What amount, or dose, may work best?
- How well does the body tolerate it?
- Are there side effects?

All medicines must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medicines.

About the EXPAND Study



The EXPAND Study is looking at a potential new medication (investigational medication) for people with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE). People with CAE and JAE have brief episodes of staring and unresponsiveness called absence seizures. These types of seizures usually last a few seconds.

CAE begins between 2 and 12 years of age and the seizures usually disappear by late childhood or mid-adolescence. JAE begins between 7 and 17 years of age and can be a lifelong condition.

The study is for people with CAE or JAE who are 2 to 25 years of age. Children and young adults will always have a say about whether or not they want to participate. However, depending on the age of the participant, they may also need the permission of a parent, guardian, or legally authorized representative.

Why is the EXPAND Study important?



Treatment options for CAE and JAE are limited. Anti-epileptic medicines that are currently available may not work for everyone, may stop working over time, or may have to be stopped due to side effects.

The investigational medication is believed to work differently from anti-epileptic medicines already approved for absence seizures.

It is hoped that the investigational medication might be an additional treatment option for people with CAE and JAE in the future.

About the investigational medication



The investigational medication in this study has been approved in several countries by health authorities to treat a different type of seizure, called a partial-onset seizure. It is not approved to treat people with CAE or JAE who have absence seizures. It is therefore called 'investigational'.

